Paraneoplastic brainstem encephalitis and anti-Ri antibodies.
Sutton
I J
IJ
Barnett
M H
MH
Watson
J D G
JD
Ell
J J
JJ
Dalmau
J
J
D000368:Aged; D000951:Antigens, Neoplasm; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001933:Brain Stem / Q000276:immunology* / Q000473:pathology / Q000503:physiopathology; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy / Q000556:secondary; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000473:pathology; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000150:complications* / Q000188:drug therapy; D009419:Nerve Tissue Proteins / Q000097:blood / Q000276:immunology*; D000090682:Neuro-Oncological Ventral Antigen; D015835:Ocular Motility Disorders / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D020361:Paraneoplastic Syndromes, Nervous System / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D016601:RNA-Binding Proteins / Q000097:blood / Q000276:immunology*; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000556:secondary; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
D000951:Antigens, Neoplasm; D009419:Nerve Tissue Proteins; D000090682:Neuro-Oncological Ventral Antigen; D016601:RNA-Binding Proteins